emtricitabine has been researched along with Genital Tract Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cottrell, M; Dellon, ES; Gonzalez, D; Kashuba, ADM; Madanick, RD; Maffuid, K; Nelson, JAE; Prince, HA; Shaheen, NJ; Srinivas, N; Sykes, C; White, N | 1 |
| Blake, KH; Chen, J; Cohen, MS; Dumond, JB; Gay, CL; Greene, SA; Kashuba, ADM; Maas, BM; Nelson, JAE; Prince, HMA; Schauer, AP; Sykes, C | 1 |
2 other study(ies) available for emtricitabine and Genital Tract Infections
| Article | Year |
|---|---|
Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Computer Simulation; Demography; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Maraviroc; Pre-Exposure Prophylaxis; Reproductive Tract Infections; Tenofovir; Treatment Outcome | 2020 |
Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
Topics: Adenine; Anti-Retroviral Agents; Blood Cells; Emtricitabine; Genitalia, Male; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Reproductive Tract Infections; Semen; Tenofovir | 2019 |